Kartesia supports Evestia Clinical in its acquisition of Atlantic Research Group

Kartesia, the European specialist provider of capital solutions for small and mid-sized companies, is pleased to announce that it has provided a senior financing solution to support Evestia Clinical (“Evestia”) in its acquisition of Atlantic Research Group (“ARG”).

Evestia is a clinical research organisation that was carved out from Bionical Emas in December 2024 by Kester Capital and its incoming management team. With specialist expertise in oncology and rare disease, Evestia is responsible for supporting its pharmaceutical and biotech clients in the management and delivery of their clinical trials. Evestia subsequently acquired ARG in July 2025, a leading clinical research organisation in the US with similar expertise in oncology and rare disease, as well as neurology. The combined Group will provide a full-service offering across the drug trial lifecycle and will expand the Group’s geographic presence.

The capital for this investment has been provided by both Kartesia’s Senior Opportunities (“KSO”) Strategy and SMAs. The team supporting the transaction at Kartesia consisted of Karan Patole, Tom O’Moore and Ines Kateb.

Karan Patole, Associate Director at Kartesia said: “We are delighted to partner with Kester Capital and support Evestia Clinical in its acquisition of Atlantic Research Group. We look forward to working closely with Evestia’s ambitious management team and we are confident that the acquisition of ARG will solidify Evestia’s position as a market leading CRO with a truly global presence. This transaction aligns with Kartesia’s strategy of supporting experienced sponsors and management teams through tailored capital solutions that enable growth through strategic expansion in supportive end markets.”

For further details please contact:

H/Advisors Maitland – Finlay Donaldson
kartesia-maitland@h-advisors.global
+44 (0) 7341 788 066